Capmatinib is a targeted therapy medication that is used to treat certain types of non-small cell lung cancer (NSCLC) that have a specific genetic mutation known as MET exon 14 skipping. This mutation causes the MET gene to produce a protein that promotes the growth and spread of cancer cells. By targeting this specific mutation, capmatinib works to inhibit the growth of cancer cells and slow down the progression of the disease.
Capmatinib is typically prescribed for patients who have already received other treatments for their NSCLC and have not seen improvement. It is taken orally in the form of tablets and is usually taken once a day with or without food. It is important to follow your healthcare provider’s instructions on how to take capmatinib and to not miss any doses.
As with any medication, capmatinib can cause side effects. Some common side effects of capmatinib may include nausea, vomiting, diarrhea, fatigue, and changes in liver function tests. It is important to report any side effects to your healthcare provider so they can help manage them and adjust your treatment plan if needed.
Before starting capmatinib, it is important to discuss your medical history and any other medications or supplements you are taking with your healthcare provider. They will be able to determine if capmatinib is the right treatment option for you and monitor your progress throughout your treatment.
Overall, capmatinib is a promising treatment option for patients with NSCLC that have the MET exon 14 skipping mutation. It is important to work closely with your healthcare provider to ensure the best possible outcome with this medication.
EN 
ES 
FR 
PT 
ZH